Article Menu

Export Article

More by Authors Links

Article Data

  • Views 3243
  • Dowloads 130

Original Research

Open Access

Oral anticoagulants in patients with chronic kidney disease and atrial fibrillation

  • INGRID PRKAČIN1
  • GORDANA CAVRIĆ1
  • VIŠNJA NESEK ADAM2
  • DIANA BALENOVIĆ3
  • IVAN HORVAT3
  • VESNA ĐERMANOVIĆ DOBROTA4
  • TOMISLAV RADOČAJ1

1Merkur University Hospital, Department of Internal Medicine, University of Zagreb, School of Medicine, Zagreb, Croatia

2University Hospital Sveti Duh, Department for Anaesthesiology, Reanimatology and Intensive Care, University of Osijek, School of Medicine, Osijek, Croatia

3General Hospital Sisak, Department of Internal Medicine, Sisak, Croatia

4Merkur University Hospital, Vuk Vrhovac Clinic for Diabetes, Endocrinology and Metabolic Diseases, University of Zagreb, School of Medicine, Zagreb, Croatia

DOI: 10.22514/SV112.062016.8 Vol.11,Issue S2,June 2016 pp.41-43

Published: 14 June 2016

*Corresponding Author(s): INGRID PRKAČIN E-mail: ingrid.prkacin@gmail.com

PDF (78.45 kB) View Full-text

Abstract

The aim of this study was to investigate the effects of new/direct oral anticoagulants (DOACs) on renal function parameters in chronic kidney disease patients with esti-mated glomerular filtration rate (eGFR) that therapy with new/direct oral antico-agulants (non-VKA oral anticoagulants) have a better bleeding risk profile and less decline in eGFR compared with vitamin K antagonists. 

Keywords

vitamin K antagonists, non-VKA oral anticoagulants, renal function

Cite and Share

INGRID PRKAČIN,GORDANA CAVRIĆ,VIŠNJA NESEK ADAM,DIANA BALENOVIĆ,IVAN HORVAT,VESNA ĐERMANOVIĆ DOBROTA,TOMISLAV RADOČAJ. Oral anticoagulants in patients with chronic kidney disease and atrial fibrillation. Signa Vitae. 2016. 11(S2);41-43.

URL:

https://www.signavitae.com/articles/10.22514/SV112.062016.8

References

1. Ball T, Wheelan K, McCullough PA. Chronic anticoagulation in chronic kidney disease. Journal of the American College of Cardiol-ogy. 2014;64(23):2483-2485.

2. Granger CB, Armaganijan LV. Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. Circulation 2012;125(1):159-164.

3. Hart RG, Eikelboom JW, Ingram AJ, Herzog CA. Anticoagulants in atrial fibrillation patients with chronic kidney diseases. Nature Reviews Nephrology 2012;8(10):569-578.

4. Pisters R, Lane DA, Niewulaat R, De Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-1100.

5. Baber U. Association of chronic kidney disease with atrial fibrillation among adults in the United States: Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol 2010;4(1):26-32.

6. Baillargeon J, Holems HM, Lin YL. Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults. Am J Med.2012;125(2):183-189.

7. Prkacin I, Cerkez-Habek J. Adverse drug evenst with warfarin in older patients. Thrombosis Research 2014;133:S46.

8. Weitz JI, Pollack CV. Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants. Thromb Haemost. 2015;114(6):1113-1126.

9. Pollack CV, Reilly PA, Eikelboom JE, Glund S, Verhamme P, Bernstein RA et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511-520.

10. Siegal DM, Curnutte JT, Connoly SJ, Lu G, Conle PB. Wiens BL. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med. 2015;373(25):2413-2424.

Submission Turnaround Time

Top